Comparisons

Side-by-side tables for compounds that are often confused, catalogued together or studied in the same models.

• BPC-157 vs TB-500

  BPC-157 and TB-500 are unrelated synthetic peptides often discussed together in tissue-repair research. This page compares their origin, structure, proposed mechanisms, evidence base, regulatory status and the analytical issues raised by combined blends.

• Ipamorelin vs CJC-1295

  Ipamorelin is a pentapeptide ghrelin receptor (GHS-R1a) agonist; CJC-1295 is a modified GHRH analogue, in some versions with an albumin-binding DAC group. This page compares their receptors, structures, research history and analytical considerations.

• Selank vs Semax

  Selank and Semax are synthetic heptapeptides developed in Russia, each ending in a Pro-Gly-Pro extension. Selank is a tuftsin analogue studied for anxiety-related effects; Semax is an ACTH(4-10) analogue studied in neurological settings.

• GHK vs GHK-Cu

  GHK is the tripeptide glycyl-L-histidyl-L-lysine; GHK-Cu is the same peptide bound to a copper(II) ion. This page explains how the free peptide and the copper complex differ in structure, research use, analysis and handling.

• Sermorelin vs Tesamorelin

  Sermorelin and tesamorelin are both analogues of growth hormone-releasing hormone. Sermorelin is the 29-residue active fragment and was once FDA-approved; tesamorelin is the full 44-residue sequence with an N-terminal modification and remains FDA-approved as Egrifta.

• Semaglutide vs Tirzepatide vs Retatrutide

  Semaglutide, tirzepatide and retatrutide are lipidated incretin-based peptides with one, two and three receptor targets. Semaglutide and tirzepatide are FDA-approved; retatrutide is investigational. This page compares their mechanisms, structures, trial programs and status.

• MOTS-c vs SS-31

  MOTS-c is a 16-residue peptide encoded in mitochondrial DNA and studied as a metabolic signal; SS-31 (elamipretide) is a synthetic tetrapeptide that targets cardiolipin. SS-31 is FDA-approved for Barth syndrome; MOTS-c is preclinical.

• PT-141 vs Melanotan II

  PT-141 (bremelanotide) and Melanotan II share the same cyclic heptapeptide core and differ only at the C-terminus: a free acid versus an amide. Bremelanotide is FDA-approved as Vyleesi; Melanotan II is unapproved.

• Semaglutide vs liraglutide

  Semaglutide and liraglutide are lipidated GLP-1 receptor agonists from the same developer, both FDA-approved. This page compares their sequence modifications, albumin-binding chemistry, trial programs, regulatory status and the analytical issues shared by lipidated peptides.

• GHRP-2 vs GHRP-6

  GHRP-2 and GHRP-6 are synthetic hexapeptide growth hormone releasing peptides that act at the ghrelin receptor. This page compares their sequences, receptor pharmacology, human physiology studies, regulatory and WADA status, and the oxidation risks shared by their tryptophan-containing structures.

• CJC-1295 vs sermorelin

  CJC-1295 and sermorelin are both GHRH(1-29) analogues that act at the GHRH receptor. This page compares the native-sequence sermorelin with the substituted, optionally albumin-binding CJC-1295, covering structure, stability, evidence, regulatory and WADA status, and identity testing.

• TB-500 vs thymosin β4

  TB-500 usually refers to a short synthetic fragment of thymosin β4, a 43-residue actin-binding protein, but the name is applied inconsistently. This page compares the two and explains why the conflation matters for identity testing, evidence interpretation and regulatory review.

• Thymosin α1 vs thymosin β4

  Thymosin α1 and thymosin β4 share a name because both were first isolated from the same thymus extract, but they are unrelated in sequence, origin and function. This page compares their structures, biology, evidence base, regulatory status and analytical concerns.

• Humanin vs MOTS-c

  Humanin and MOTS-c are mitochondrial-derived peptides encoded within mitochondrial ribosomal RNA genes. This page compares their discovery, sequences, proposed mechanisms, research areas, evidence level, regulatory status and analytical concerns.

• Afamelanotide vs Melanotan II

  Afamelanotide and Melanotan II are synthetic α-MSH analogues that act at melanocortin receptors. Afamelanotide is FDA-approved for erythropoietic protoporphyria; Melanotan II is unapproved. This page compares their structures, receptor selectivity, evidence, regulatory status and analytics.

• Teriparatide vs abaloparatide

  Teriparatide and abaloparatide are FDA-approved anabolic peptides for osteoporosis that act at the PTH1 receptor. This page compares their origins in PTH and PTHrP, structures, proposed signaling differences, pivotal trials, regulatory status and analytical concerns.

• Gonadorelin vs kisspeptin-10

  Gonadorelin is synthetic GnRH, acting directly on pituitary gonadotrophs, while kisspeptin-10 acts one step upstream on GnRH neurons. This page compares their sequences, place in the reproductive axis, research uses, regulatory and WADA status, and analytical concerns.

• Argireline vs Matrixyl

  Argireline (acetyl hexapeptide-8) and Matrixyl (palmitoyl pentapeptide-4) are cosmetic peptide ingredients studied for different reasons: one for interference with SNARE complex assembly, the other as a matrix-signaling fragment. This page compares their structures, proposed mechanisms, evidence and analytics.

• Ipamorelin vs MK-677

  Ipamorelin is a synthetic pentapeptide and MK-677 (ibutamoren) an orally active small molecule, yet both are agonists at the ghrelin receptor GHS-R1a. This page compares their chemistry, pharmacology, clinical research, regulatory and WADA status, and the different analytical methods each requires.

• Epitalon vs pinealon

  Epitalon and pinealon are short synthetic peptides from the same Russian bioregulator research program, a tetrapeptide and a tripeptide respectively. This page compares their sequences, origins, proposed mechanisms, evidence quality, regulatory status and analytical concerns.